Literature DB >> 17914053

Treatment with convalescent plasma for influenza A (H5N1) infection.

Boping Zhou, Nanshan Zhong, Yi Guan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17914053     DOI： 10.1056/NEJMc070359

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  197 in total

1.  An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses.

Authors:  Hsueh-Ling Janice Oh; Sara Akerström; Shuo Shen; Sándor Bereczky; Helen Karlberg; Jonas Klingström; Sunil K Lal; Ali Mirazimi; Yee-Joo Tan
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

2.  Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations.

Authors:  David K Hong; Adriana H Tremoulet; Jane C Burns; David B Lewis
Journal:  Pediatr Infect Dis J       Date:  2011-01       Impact factor: 2.129

Review 3.  Convalescent plasma: new evidence for an old therapeutic tool?

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Liviana Catalano; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

4.  Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China.

Authors:  Xingui Tian; Zaixue Jiang; Qiang Ma; Qian Liu; Xiaomei Lu; Wenkuan Liu; Xiaohong Liao; Rong Zhou; Xiaobo Su; Qingming Luo
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

5.  Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir.

Authors:  Huanhuan Ren; Guiqin Wang; Shuangshuang Wang; Honglin Chen; Zhiwei Chen; Hongxing Hu; Genhong Cheng; Paul Zhou
Journal:  MAbs       Date:  2016-05-11       Impact factor: 5.857

6.  Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.

Authors:  John H Beigel; Jocelyn Voell; Chiung-yu Huang; Peter D Burbelo; H Clifford Lane
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

7.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

8.  Structural and functional definition of a vulnerable site on the hemagglutinin of highly pathogenic avian influenza A virus H5N1.

Authors:  Pengfei Wang; Yanan Zuo; Jianfeng Sun; Teng Zuo; Senyan Zhang; Shichun Guo; Xuanling Shi; Mifang Liang; Paul Zhou; Linqi Zhang; Xinquan Wang
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157

9.  Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses.

Authors:  Lina Sun; Xiuhua Lu; Chuan Li; Min Wang; Qinzhi Liu; Zi Li; Xiaofen Hu; Jiandong Li; Feng Liu; Qun Li; Jessica A Belser; Kathy Hancock; Yuelong Shu; Jacqueline M Katz; Mifang Liang; Dexin Li
Journal:  PLoS One       Date:  2009-05-07       Impact factor: 3.240

10.  Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza.

Authors:  Garry W Lynch; Paul Selleck; John S Sullivan
Journal:  J Mol Genet Med       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.